Molecule for treating an inflammatory disorder
AssigneesProsensa Technologies B.V., Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
InventorsGarrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus, Judith Christina Theodora Van Deutekom, Josephus Johannes De Kimpe, Joseph Stephan Verbeek, Aliye Seda Ylmaz-Elis
Life of this patent
Estimating the term…
Abstract
The invention provides two types of oligonucleotides for treating an inflammatory disorder: an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a C5 in order to decrease the amount of a C5a and an oligonucleotide which is able of altering the splicing of a pre-mRNA encoding a IL-1RAcP in order to increase the amount of a soluble IL-1RAcP. The invention further provides the use of said oligonucleotides for preventing or treating an inflammatory disorder.
Claims23
An oligonucleotide which alters the splicing of a pre-mRNA encoding IL-1RAcP, wherein said oligonucleotide binds a part of exon 9 in the pre-mRNA encoding IL-1RAcP, wherein exon 9 comprises SEQ ID NO:
- 5 or 6, said oligonucleotide comprising a modification selected from the group consisting of:
- a modification to increase resistance to RNAseH within a cell, a backbone modification and/or a sugar modification.
A method for preventing or treating an inflammatory disorder in an individual, the method comprising administering to said individual an effective amount of an oligonucleotide wherein said oligonucleotide alters the splicing of a pre-mRNA encoding IL-1RAcP, binds a part of exon 9 of the IL-1RAcP pre-mRNA, wherein exon 9 comprises SEQ ID NO:
- 5 or 6, said oligonucleotide comprising a modification selected from the group consisting of:
- a modification to increase resistance to RNAseH within a cell, a backbone modification, and/or a sugar modification.
An oligonucleotide which alters the splicing of a pre-mRNA encoding IL-1RAcP, wherein said oligonucleotide binds a part of a non-exon region of the pre-mRNA encoding IL-1RAcP, wherein exon 9 in the pre-mRNA encoding IL-1RAcP comprises SEQ ID NO:
- 5 or 6;
- wherein said oligonucleotide induces the skipping of exon 9 in the pre-mRNA encoding IL-1RAcP, and wherein said oligonucleotide comprises a modification selected from the group consisting of:
- a modification to increase resistance to RNAseH within a cell, a backbone modification and/or a sugar modification.
Dependencies are inferred from the claim text.